cGMP is the second messenger of

Explanation

## Correct Answer: B. NO (nitric oxide) cGMP (cyclic guanosine monophosphate) is the canonical second messenger of **nitric oxide (NO)**. NO is a gaseous signaling molecule synthesized by endothelial cells and other tissues via the enzyme nitric oxide synthase (NOS). When NO diffuses into target cells (particularly vascular smooth muscle), it binds to and activates **soluble guanylate cyclase**, which catalyzes the conversion of GTP to cGMP. Elevated intracellular cGMP activates **protein kinase G (PKG)**, leading to smooth muscle relaxation and vasodilation. This NO-cGMP-PKG pathway is central to endothelium-dependent vasodilation, blood pressure regulation, and erectile function. In Indian clinical practice, phosphodiesterase-5 inhibitors (sildenafil, tadalafil) are widely used to block cGMP degradation, prolonging the NO signal in erectile dysfunction and pulmonary hypertension. The NO-cGMP axis is also critical in septic shock pathophysiology, where excessive NO production contributes to refractory hypotension. This is the most direct and physiologically established second messenger relationship among the options. ## Why the other options are wrong **A. ADH** — ADH (vasopressin) uses **cAMP**, not cGMP, as its second messenger. ADH binds to V2 receptors on renal collecting duct cells, activating adenylate cyclase to generate cAMP, which increases aquaporin-2 expression and water reabsorption. This is a classic cAMP-mediated response, not cGMP. NBE may trap students who confuse all G-protein-coupled receptor signaling as using the same second messenger. **C. Angiotensin II** — Angiotensin II primarily uses **IP3 and DAG** (inositol 1,4,5-trisphosphate and diacylglycerol) as second messengers via phospholipase C activation, leading to intracellular calcium release and vasoconstriction. Although some cGMP effects may occur indirectly, the primary and direct second messenger pathway for Ang II is phosphoinositide hydrolysis, not cGMP. This is a common distractor for students unfamiliar with the specificity of second messenger systems. **D. Somatostatin** — Somatostatin acts via **G-protein-coupled receptors that inhibit adenylate cyclase**, thereby **decreasing cAMP** levels. It does not activate guanylate cyclase or generate cGMP. Somatostatin's inhibitory effects on hormone secretion and smooth muscle are mediated by cAMP reduction and potassium channel opening, not cGMP elevation. This option exploits confusion between different inhibitory signaling pathways. ## High-Yield Facts - **NO-cGMP-PKG axis**: Nitric oxide activates soluble guanylate cyclase → cGMP ↑ → PKG activation → smooth muscle relaxation and vasodilation. - **Phosphodiesterase-5 inhibitors** (sildenafil, tadalafil) block cGMP degradation; widely used in India for erectile dysfunction and pulmonary hypertension. - **ADH uses cAMP**, not cGMP; Angiotensin II uses IP3/DAG; Somatostatin decreases cAMP—each hormone has a distinct second messenger. - **Endothelium-dependent vasodilation** is mediated by NO-cGMP signaling; loss of this pathway contributes to hypertension and atherosclerosis in Indian populations. - **Septic shock pathophysiology**: Excessive iNOS-derived NO → cGMP ↑ → refractory vasodilation and hypotension; selective iNOS inhibitors are investigational. ## Mnemonics **NO-cGMP Memory Hook** **NO** → **G**uanylate cyclase → **cGMP**. Think: "NO makes the G-enzyme work" (G = guanylate). Contrast with ADH/Ang II which use different messengers. **Second Messenger Pairing (NEET Classic)** **cAMP**: ADH, epinephrine, glucagon, ACTH. **cGMP**: NO, natriuretic peptides. **IP3/DAG**: Angiotensin II, TRH, GnRH. Use this to eliminate wrong options instantly. ## NBE Trap NBE pairs NO with cGMP to test whether students know the specific second messenger for each hormone. The trap is offering ADH (which uses cAMP) and Angiotensin II (which uses IP3/DAG) as distractors—students who confuse "G-protein-coupled receptor = cAMP" or "vasodilator = cAMP" will fall into this trap. ## Clinical Pearl In Indian clinical practice, the NO-cGMP axis is exploited therapeutically in two major scenarios: (1) erectile dysfunction and pulmonary hypertension, where PDE-5 inhibitors prolong cGMP signaling, and (2) septic shock, where excessive iNOS-derived NO causes refractory hypotension—understanding this pathway is essential for managing both common outpatient and critical care presentations. _Reference: Guyton & Hall Textbook of Medical Physiology (Ch. 61 – Blood Pressure Regulation); Harrison's Principles of Internal Medicine (Ch. 297 – Vascular Biology); KD Tripathi Essentials of Medical Pharmacology (Ch. 10 – Vasodilators)_